Product Description
Samyang was developing syp-1018, an intravenous CYP51 Inhibitor for Systemic Mycotic Infection
Mechanisms of Action: CYP51 Inhibitor
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Samyang
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Vfend | P1 |
Completed |
Healthy Volunteers |
2012-11-01 |